Alvotech公司和Teva公司在2025年12月19日在美国为AVT06号运载火箭的发射清理了道路,等待批准,解决了有关生物相似的Eylea的专利争端。 Alvotech and Teva settled patent disputes over biosimilar Eylea, clearing path for AVT06 launch in the U.S. on Dec. 19, 2025, pending approval.

Alvotech公司和Teva公司已商定在美国解决AVT06的解决日期,AVT06是拟议的与眼疾药物Eylea类似的生物,解决专利纠纷,并为潜在的市场进入铺平道路。 Alvotech and Teva have agreed on a settlement date in the U.S. for AVT06, a proposed biosimilar to the eye disease drug Eylea®, resolving patent disputes and paving the way for potential market entry. 该协议于2025年12月19日生效,允许Teva在规定期限后在美国发射AVT06,但须经监管批准。 The agreement, effective December 19, 2025, allows Teva to launch AVT06 in the U.S. after a specified period, subject to regulatory approval. 这一发展可能会加剧因与年龄有关的乳腺畸形和其他视网膜条件而导致的湿龄治疗市场的竞争。 This development could increase competition in the treatment market for wet age-related macular degeneration and other retinal conditions.